Monocyte-derived circulating microparticles (CD14+, CD14+/CD11b+ and CD14+/CD142+) are related to long-term prognosis for cardiovascular mortality in STEMI patients

International Journal of Cardiology

Volumn 227, Issue , 2017, Pages 876-881

  Chiva Blanch, Gemma ^a,b,c,d   Bratseth, Vibeke ^a   Ritschel, Vibeke ^a,b   Andersen, Geir Ø ^a   Halvorsen, Sigrun ^a,b   Eritsland, Jan ^a   Arnesen, Harald ^a,b   Badimon, Lina ^c   Seljeflot, Ingebjørg ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Institut Català de Ciències Cardiovasculars   (Spain)

^d BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

Cardiovascular mortality; Circulating microparticles; Monocytes; STEMI; Tissue factor

Indexed keywords

THROMBOPLASTIN; BIOLOGICAL MARKER; CD11B ANTIGEN; CD14 ANTIGEN; ITGAM PROTEIN, HUMAN;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLOW CYTOMETER; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; LEUKOCYTE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; MONOCYTE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE; BLOOD; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; MORTALITY; ST ELEVATION MYOCARDIAL INFARCTION; TIME FACTOR; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD11B; ANTIGENS, CD14; BIOMARKERS; CELL-DERIVED MICROPARTICLES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MONOCYTES; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDIES; ST ELEVATION MYOCARDIAL INFARCTION; THROMBOPLASTIN; TIME FACTORS;

EID: 85003837127     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.11.302     Document Type: Article

References (31)

1. [1] van der Pol, E., Boing, A.N., Harrison, P., Sturk, A., Nieuwland, R., Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol. Rev. 64:3 (2012), 676–705.
2. [2] Suades, R., Padro, T., Badimon, L., The role of blood-borne microparticles in inflammation and hemostasis. Semin. Thromb. Hemost. 41:6 (2015), 590–606.
3. [3] Mallat, Z., Benamer, H., Hugel, B., Benessiano, J., Steg, P.G., Freyssinet, J.M., et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 101:8 (2000), 841–843.
4. [4] Giannopoulos, G., Oudatzis, G., Paterakis, G., Synetos, A., Tampaki, E., Bouras, G., et al. Red blood cell and platelet microparticles in myocardial infarction patients treated with primary angioplasty. Int. J. Cardiol. 176:1 (2014), 145–150.
5. [5] Morel, O., Hugel, B., Jesel, L., Mallat, Z., Lanza, F., Douchet, M.P., et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J. Thromb. Haemost. 2:7 (2004), 1118–1126.
6. [6] Suades, R., Padro, T., Crespo, J., Ramaiola, I., Martin-Yuste, V., Sabate, M., et al. Circulating microparticle signature in coronary and peripheral blood of ST elevation myocardial infarction patients in relation to pain-to-PCI elapsed time. Int. J. Cardiol. 202 (2016), 378–387.
7. [7] Chiva-Blanch, G., Suades, R., Crespo, J., Vilahur, G., Arderiu, G., Padro, T., et al. CD3/CD45 and SMA-alpha circulating microparticles are increased in individuals at high cardiovascular risk who will develop a major cardiovascular event. Int. J. Cardiol. 208 (2016), 147–149.
8. [8] Burns, R.J., Gibbons, R.J., Yi, Q., Roberts, R.S., Miller, T.D., Schaer, G.L., et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J. Am. Coll. Cardiol. 39:1 (2002), 30–36.
9. [9] Liuzzo, G., Biasucci, L.M., Gallimore, J.R., Grillo, R.L., Rebuzzi, A.G., Pepys, M.B., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. J. Med. 331:7 (1994), 417–424.
10. [10] Lacroix, R., Judicone, C., Mooberry, M., Boucekine, M., Key, N.S., Dignat-George, F., et al. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative Workshop. J. Thromb. Haemost., 2013, 10.1111/jth.12207.
11. [11] Nieuwland, R., Berckmans, R.J., McGregor, S., Boing, A.N., Romijn, F.P., Westendorp, R.G., et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 95:3 (2000), 930–935.
12. [12] Jaremo, P., Nilsson, O., Interleukin-6 and neutrophils are associated with long-term survival after acute myocardial infarction. Eur. J. Intern. Med. 19:5 (2008), 330–333.
13. [13] Ritschel, V.N., Seljeflot, I., Arnesen, H., Halvorsen, S., Eritsland, J., Fagerland, M.W., et al. Circulating levels of IL-6 receptor and gp130 and long-term clinical outcomes in ST-elevation myocardial infarction. J. Am. Heart Assoc., 5(6), 2016.
14. [14] Zaret, B.L., Wackers, F.J., Terrin, M.L., Forman, S.A., Williams, D.O., Knatterud, G.L., et al. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group. J. Am. Coll. Cardiol. 26:1 (1995), 73–79.
15. [15] Mather, A.N., Fairbairn, T.A., Artis, N.J., Greenwood, J.P., Plein, S., Relationship of cardiac biomarkers and reversible and irreversible myocardial injury following acute myocardial infarction as determined by cardiovascular magnetic resonance. Int. J. Cardiol. 166:2 (2013), 458–464.
16. [16] Nguyen, T.L., Phan, J.A., Hee, L., Moses, D.A., Otton, J., Terreblanche, O.D., et al. High-sensitivity troponin T predicts infarct scar characteristics and adverse left ventricular function by cardiac magnetic resonance imaging early after reperfused acute myocardial infarction. Am. Heart J. 170:4 (2015), 715–725, e2.
17. [17] Sinning, J.M., Losch, J., Walenta, K., Bohm, M., Nickenig, G., Werner, N., Circulating CD31 +/Annexin V + microparticles correlate with cardiovascular outcomes. Eur. Heart J. 32:16 (2011), 2034–2041.
18. [18] Nozaki, T., Sugiyama, S., Koga, H., Sugamura, K., Ohba, K., Matsuzawa, Y., et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J. Am. Coll. Cardiol. 54:7 (2009), 601–608.
19. [19] Nozaki, T., Sugiyama, S., Sugamura, K., Ohba, K., Matsuzawa, Y., Konishi, M., et al. Prognostic value of endothelial microparticles in patients with heart failure. Eur. J. Heart Fail. 12:11 (2010), 1223–1228.
20. [20] Satta, N., Toti, F., Feugeas, O., Bohbot, A., Dachary-Prigent, J., Eschwege, V., et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J. Immunol. 153:7 (1994), 3245–3255.
21. [21] Aharon, A., Tamari, T., Brenner, B., Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb. Haemost. 100:5 (2008), 878–885.
22. [22] Falati, S., Liu, Q., Gross, P., Merrill-Skoloff, G., Chou, J., Vandendries, E., et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp. Med. 197:11 (2003), 1585–1598.
23. [23] Eikendal, A.L., den Ruijter, H.M., Uiterwaal, C.S., Pasterkamp, G., Hoefer, I.E., de Kleijn, D.P., et al. Extracellular vesicle protein CD14 relates to common carotid intima-media thickness in eight-year-old children. Atherosclerosis 236:2 (2014), 270–276.
24. [24] Vrijenhoek, J.E., Pasterkamp, G., Moll, F.L., de Borst, G.J., Bots, M.L., Catanzariti, L., et al. Extracellular vesicle-derived CD14 is independently associated with the extent of cardiovascular disease burden in patients with manifest vascular disease. Eur. J. Prev. Cardiol. 22:4 (2015), 451–457.
25. [25] Kanhai, D.A., Visseren, F.L., van der Graaf, Y., Schoneveld, A.H., Catanzariti, L.M., Timmers, L., et al. Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. Int. J. Cardiol. 168:3 (2013), 2358–2363.
26. [26] Goto, S., Tamura, N., Li, M., Handa, M., Ikeda, Y., Handa, S., et al. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J. Thromb. Haemost. 1:9 (2003), 2022–2030.
27. [27] Matzdorff, A.C., Kuhnel, G., Kemkes-Matthes, B., Pralle, H., Voss, R., Fareed, J., Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro. J. Lab. Clin. Med. 135:3 (2000), 247–255.
28. [28] Gemmell, C.H., Sefton, M.V., Yeo, E.L., Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J. Biol. Chem. 268:20 (1993), 14586–14589.
29. [29] Li, X., Cong, H., Platelet-derived microparticles and the potential of glycoprotein IIb/IIIa antagonists in treating acute coronary syndrome. Tex. Heart Inst. J. 36:2 (2009), 134–139.
30. [30] Chiva-Blanch, G., Suades, R., Padro, T., Vilahur, G., Pena, E., Ybarra, J., et al. Microparticle shedding by erythrocytes, monocytes and vascular smooth muscular cells is reduced by aspirin in diabetic patients. Rev. Esp. Cardiol. 69 (2016), 672–680.
31. [31] Suades, R., Padro, T., Alonso, R., Mata, P., Badimon, L., Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. Thromb. Haemost. 110:2 (2013), 366–377.